Operative profile, safety and functional outcomes after GreenLight laser prostate surgery: results from a 12 months follow-up multicenter Italian cohort analyses.


Journal

Minerva urologica e nefrologica = The Italian journal of urology and nephrology
ISSN: 1827-1758
Titre abrégé: Minerva Urol Nefrol
Pays: Italy
ID NLM: 8503649

Informations de publication

Date de publication:
Oct 2020
Historique:
pubmed: 15 4 2020
medline: 13 3 2021
entrez: 15 4 2020
Statut: ppublish

Résumé

Over the two past decades, GreenLight laser therapy has been considered a valid alternative for the treatment of lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia/benign prostatic obstruction (BPH/BPO). However, the debate on the effectiveness of laser therapy compared to conventional techniques is still open. The aim of our study is to analyze and describe the use of GreenLight laser prostate surgery in Italy, with regard to the surgical techniques performed and the surgical and functional outcomes at mid-term follow-up. From March 2012 to July 2018, patients who underwent GreenLight laser prostate surgery for LUTS due to BPH/BPO from 19 Italian centers were included. The following parameters were evaluated in the population: age, prostate volume, prostate adenoma volume, PSA tot, Q<inf>max</inf> at uroflowmetry (UFM), International Prostatic Symptoms Score (IPSS), previous therapy for LUTS, use of anticoagulants and antiplatelet drugs. We recorded also the kind of anesthesia, mean laser time (min), mean irradiation time (min), TURP conversion/completion rate, postoperative day of catheter removal, postoperative acute urinary retention (AUR), hospital stay, variation of hematocrit (Ht) and hemoglobin levels (Hb). Early complications were classified according to the Clavien-Dindo classification, the re-operation rate within 30 days and after 30 days, the late complications and the Patient Global Impression of Improvement were also collected. Changes over time in terms of blood loss and functional outcomes (IPSS and Q<inf>max</inf> at the UFM at 6 and 12 months) were tested with Student's test for paired samples. We assumed P≤0.05 as level of statistical significance. Overall, 1077 were enrolled in the study, 554 (56.4%) were treated with standard vaporization and 523 (48.6%) with anatomical vaporization. Student's t-test for paired samples showed no statistically significant differences in terms of reduction of Ht preoperative vs. Ht postoperative (42.80±3.91 vs. 39.93±5.35 95% CI P=0.3) and preintervention and postintervention Hb levels (14.28±1.46 vs. 13.72 P=0.35). Compared with the preoperative Q<inf>max</inf> (8.60±2.64), the 6- and 12-month UFM showed a significant improvement [19.56±6.29, P<0.01 and 19.99±5.92 P<0.01]. In terms of IPSS variation, compared to the baseline level (22±5.51) the 6- and 12-month follow-up confirmed a significant reduction (8.01±4.41 P<0.01 and 5.81±4.12 P<0.01 respectively). Postoperative complications were CD0, CD1, CD2, CD3, CD4 in 33.0%,35.3%, 2.9%, 0.3%, and 0.6%. To the best of our knowledge, this is one of the most numerous surgical series of GreenLight laser vaporization and with the longest follow-up. This technique should be considered as a safe and effective alternative in the treatment of secondary LUTS to BPH.

Sections du résumé

BACKGROUND BACKGROUND
Over the two past decades, GreenLight laser therapy has been considered a valid alternative for the treatment of lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia/benign prostatic obstruction (BPH/BPO). However, the debate on the effectiveness of laser therapy compared to conventional techniques is still open. The aim of our study is to analyze and describe the use of GreenLight laser prostate surgery in Italy, with regard to the surgical techniques performed and the surgical and functional outcomes at mid-term follow-up.
METHODS METHODS
From March 2012 to July 2018, patients who underwent GreenLight laser prostate surgery for LUTS due to BPH/BPO from 19 Italian centers were included. The following parameters were evaluated in the population: age, prostate volume, prostate adenoma volume, PSA tot, Q<inf>max</inf> at uroflowmetry (UFM), International Prostatic Symptoms Score (IPSS), previous therapy for LUTS, use of anticoagulants and antiplatelet drugs. We recorded also the kind of anesthesia, mean laser time (min), mean irradiation time (min), TURP conversion/completion rate, postoperative day of catheter removal, postoperative acute urinary retention (AUR), hospital stay, variation of hematocrit (Ht) and hemoglobin levels (Hb). Early complications were classified according to the Clavien-Dindo classification, the re-operation rate within 30 days and after 30 days, the late complications and the Patient Global Impression of Improvement were also collected. Changes over time in terms of blood loss and functional outcomes (IPSS and Q<inf>max</inf> at the UFM at 6 and 12 months) were tested with Student's test for paired samples. We assumed P≤0.05 as level of statistical significance.
RESULTS RESULTS
Overall, 1077 were enrolled in the study, 554 (56.4%) were treated with standard vaporization and 523 (48.6%) with anatomical vaporization. Student's t-test for paired samples showed no statistically significant differences in terms of reduction of Ht preoperative vs. Ht postoperative (42.80±3.91 vs. 39.93±5.35 95% CI P=0.3) and preintervention and postintervention Hb levels (14.28±1.46 vs. 13.72 P=0.35). Compared with the preoperative Q<inf>max</inf> (8.60±2.64), the 6- and 12-month UFM showed a significant improvement [19.56±6.29, P<0.01 and 19.99±5.92 P<0.01]. In terms of IPSS variation, compared to the baseline level (22±5.51) the 6- and 12-month follow-up confirmed a significant reduction (8.01±4.41 P<0.01 and 5.81±4.12 P<0.01 respectively). Postoperative complications were CD0, CD1, CD2, CD3, CD4 in 33.0%,35.3%, 2.9%, 0.3%, and 0.6%.
CONCLUSIONS CONCLUSIONS
To the best of our knowledge, this is one of the most numerous surgical series of GreenLight laser vaporization and with the longest follow-up. This technique should be considered as a safe and effective alternative in the treatment of secondary LUTS to BPH.

Identifiants

pubmed: 32284526
pii: S0393-2249.20.03597-3
doi: 10.23736/S0393-2249.20.03597-3
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

622-628

Auteurs

Giulio Reale (G)

Department of Urology, S. Maria delle Croci Hospital, Azienda AUSL Romagna, Ravenna, Italy - dottorgreale@gmail.com.

Michele Marchioni (M)

Department of Medical, Oral and Biotechnological Sciences, G. D'Annunzio University, Chieti, Italy.

Vincenzo Altieri (V)

Department of Urology, Humanitas Gavazzeni, Bergamo, Italy.

Francesco Greco (F)

Department of Urology, Humanitas Gavazzeni, Bergamo, Italy.

Cosimo De Nunzio (C)

Department of Urology, Sant'Andrea Hospital, Sapienza University, Rome, Italy.

Paolo Destefanis (P)

Departement of Urology, Molinette Hospital, Città della Salute e della Scienza, Turin, Italy.

Stefano Ricciardulli (S)

Department of Urology, Arcispedale Santa Maria Nuova, Reggio Emilia, Italy.

Franco Bergamaschi (F)

Department of Urology, Arcispedale Santa Maria Nuova, Reggio Emilia, Italy.

Giuseppe Fasolis (G)

Department of Urology, S. Lazzaro Hospital, Alba, Cuneo, Italy.

Francesco Varvello (F)

Department of Urology, S. Lazzaro Hospital, Alba, Cuneo, Italy.

Salvatore Voce (S)

Department of Urology, S. Maria delle Croci Hospital, Azienda AUSL Romagna, Ravenna, Italy.

Fabiano Palmieri (F)

Department of Urology, S. Maria delle Croci Hospital, Azienda AUSL Romagna, Ravenna, Italy.

Claudio Divan (C)

Department of Urology, Hospital of Rovereto, Rovereto, Milan, Italy.

Gianni Malossini (G)

Department of Urology, Hospital of Rovereto, Rovereto, Milan, Italy.

Rino Oriti (R)

Department of Urology, Ulivella e Glicini Clinic, Florence, Italy.

Agostino Tuccio (A)

Unit of Oncologic Minimally-Invasive Urology and Andrology, Department of Urology, Careggi Hospital, University of Florence, Florence, Italy.

Lorenzo Ruggera (L)

Department of Urology, Urologic Clinic, University of Padua, Padua, Italy.

Andrea Tubaro (A)

Department of Urology, Sant'Andrea Hospital, Sapienza University, Rome, Italy.

Giampaolo Delicato (G)

Department of Urology, S.Giovanni Evangelista Hospital, Tivoli, Rome, Italy.

Antonino Laganà (A)

Department of Urology, S.Giovanni Evangelista Hospital, Tivoli, Rome, Italy.

Claudio Dadone (C)

Department of Urology, Santa Croce e Carle Hospital, Cuneo, Italy.

Gaetano De Rienzo (G)

Urology and Andrology Unit II, Department of Emergency and Organ Transplantation, University of Bari, Bari, Italy.

Andrea Ditonno (A)

Urology and Andrology Unit II, Department of Emergency and Organ Transplantation, University of Bari, Bari, Italy.

Antonio Frattini (A)

Department of Urology, Ospedale Civile di Guastalla, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.
Ercole Franchini di Montecchio Emilia Hospital, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.

Luigi Pucci (L)

Department of Urology, AORN Antonio Cardarelli, Naples, Italy.

Maurizio Carrino (M)

Department of Urology, AORN Antonio Cardarelli, Naples, Italy.

Franco Montefiore (F)

Department of Urology, San Giacomo Hospital, Novi Ligure, Alessandria, Italy.

Stefano Germani (S)

Unit of Urology, Department of Surgery, Tor Vergata Polyclinic Foundation, Tor Vergata University, Rome, Italy.

Roberto Miano (R)

Unit of Urology, Department of Surgery, Tor Vergata Polyclinic Foundation, Tor Vergata University, Rome, Italy.

Luigi Schips (L)

Department of Medical, Oral and Biotechnological Sciences, G. D'Annunzio University, Chieti, Italy.

Salvatore Rabito (S)

Department of Urology, Hesperia Hospital, Modena, Italy.

Giovanni Ferrari (G)

Department of Urology, Hesperia Hospital, Modena, Italy.

Luca Cindolo (L)

Department of Urology, Villa Stuart Private Hospital, Rome, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH